NASDAQ:EVAX Evaxion Biotech A/S (EVAX) Stock Price, News & Analysis $2.95 -0.11 (-3.59%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Evaxion Biotech A/S Stock (NASDAQ:EVAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evaxion Biotech A/S alerts:Sign Up Key Stats Today's Range$2.88▼$3.1350-Day Range$2.30▼$3.4652-Week Range$2.26▼$13.61Volume27,374 shsAverage Volume251,308 shsMarket Capitalization$15.96 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingBuy Company OverviewEvaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Read More… Next opportunity for crypto millions (Ad)The floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine… Go here to discover the crypto that's about to leave Wall Street in the dust. Evaxion Biotech A/S Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks61st Percentile Overall ScoreEVAX MarketRank™: Evaxion Biotech A/S scored higher than 61% of companies evaluated by MarketBeat, and ranked 431st out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEvaxion Biotech A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvaxion Biotech A/S has only been the subject of 1 research reports in the past 90 days.Read more about Evaxion Biotech A/S's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Evaxion Biotech A/S are expected to decrease in the coming year, from ($0.24) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evaxion Biotech A/S is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evaxion Biotech A/S is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Evaxion Biotech A/S's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.41% of the outstanding shares of Evaxion Biotech A/S have been sold short.Short Interest Ratio / Days to CoverEvaxion Biotech A/S has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evaxion Biotech A/S has recently decreased by 35.19%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvaxion Biotech A/S does not currently pay a dividend.Dividend GrowthEvaxion Biotech A/S does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.41% of the outstanding shares of Evaxion Biotech A/S have been sold short.Short Interest Ratio / Days to CoverEvaxion Biotech A/S has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evaxion Biotech A/S has recently decreased by 35.19%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.39 News SentimentEvaxion Biotech A/S has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Evaxion Biotech A/S this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Evaxion Biotech A/S to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Evaxion Biotech A/S insiders have not sold or bought any company stock.Percentage Held by Insiders41.64% of the stock of Evaxion Biotech A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.04% of the stock of Evaxion Biotech A/S is held by institutions.Read more about Evaxion Biotech A/S's insider trading history. Receive EVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evaxion Biotech A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address EVAX Stock News HeadlinesClinical Evidence Supports Advancement of Evaxion's AI-Immunology PlatformOctober 5 at 1:54 AM | msn.comEvaxion Biotech Charts Future with Innovative Immune TherapiesOctober 4 at 7:13 PM | finance.yahoo.comNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine… October 6, 2024 | Crypto 101 Media (Ad)Evaxion Biotech: Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology platformOctober 3 at 12:43 PM | finanznachrichten.deRecent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platformOctober 3 at 8:00 AM | globenewswire.comEvaxion Biotech A/S (NASDAQ:EVAX) and Regen BioPharma (OTCMKTS:RGBP) Financial AnalysisOctober 3 at 1:59 AM | americanbankingnews.comEvaxion Biotech A/S (NASDAQ:EVAX) Rating Reiterated by HC WainwrightSeptember 28, 2024 | americanbankingnews.comEvaxion Biotech (EVAX) Gets a Buy from Lake StreetSeptember 27, 2024 | markets.businessinsider.comSee More Headlines EVAX Stock Analysis - Frequently Asked Questions How have EVAX shares performed this year? Evaxion Biotech A/S's stock was trading at $6.8570 at the beginning of the year. Since then, EVAX shares have decreased by 57.0% and is now trading at $2.95. View the best growth stocks for 2024 here. How were Evaxion Biotech A/S's earnings last quarter? Evaxion Biotech A/S (NASDAQ:EVAX) released its earnings results on Wednesday, August, 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by $0.14. The company had revenue of $0.15 million for the quarter, compared to analysts' expectations of $0.10 million. When did Evaxion Biotech A/S's stock split? Evaxion Biotech A/S shares reverse split on Monday, January 22nd 2024. The 1-10 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Evaxion Biotech A/S IPO? Evaxion Biotech A/S (EVAX) raised $31 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. served as the underwriter for the IPO and Ladenburg Thalmann was co-manager. How do I buy shares of Evaxion Biotech A/S? Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/14/2024Today10/05/2024Next Earnings (Estimated)12/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:EVAX CUSIPN/A CIK1828253 Webwww.evaxion-biotech.com Phone45-5353-1850FaxN/AEmployees49Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$14.00 Low Stock Price Target$8.00 Potential Upside/Downside+272.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($4.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,120,000.00 Net MarginsN/A Pretax Margin-5,752.88% Return on EquityN/A Return on Assets-108.14% Debt Debt-to-Equity Ratio7.99 Current Ratio2.80 Quick Ratio2.80 Sales & Book Value Annual Sales$278,000.00 Price / Sales57.42 Cash FlowN/A Price / Cash FlowN/A Book Value($1.17) per share Price / Book-2.52Miscellaneous Outstanding Shares5,411,000Free Float3,158,000Market Cap$15.96 million OptionableNo Data Beta-0.26 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:EVAX) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHow much money are you leaving on the table from the stocks you already own?Charles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash...Unstoppable Prosperity | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion Biotech A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion Biotech A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.